Cargando…

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals

BACKGROUND: Psilocybin is a psychedelic drug that has shown lasting positive effects on clinical symptoms and self-reported well-being following a single dose. There has been little research into the long-term effects of psilocybin on brain connectivity in humans. AIM: Evaluate changes in resting-st...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCulloch, Drummond E-Wen, Madsen, Martin Korsbak, Stenbæk, Dea Siggaard, Kristiansen, Sara, Ozenne, Brice, Jensen, Peter Steen, Knudsen, Gitte Moos, Fisher, Patrick MacDonald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801642/ https://www.ncbi.nlm.nih.gov/pubmed/34189985 http://dx.doi.org/10.1177/02698811211026454

Ejemplares similares

Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
por: Søndergaard, Anna, et al.
Publicado: (2022)

Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report
por: McCulloch, Drummond E-Wen, et al.
Publicado: (2022)

Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation
por: Burmester, Daniel Rødbro, et al.
Publicado: (2022)

Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)
por: Jensen, Mathias Ebbesen, et al.
Publicado: (2022)

Default mode network functional connectivity negatively associated with trait openness to experience
por: Marstrand-Joergensen, Maja Rou, et al.
Publicado: (2021)

Evaluating cognitive disturbances as treatment target and predictor of antidepressant action in major depressive disorder: A NeuroPharm study
por: Dam, Vibeke Høyrup, et al.
Publicado: (2022)

Music programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
por: Messell, Catharina, et al.
Publicado: (2022)

A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT(2A) Receptor Density in the Pig Brain
por: Raval, Nakul Ravi, et al.
Publicado: (2021)

Brain serotonin transporter is associated with cognitive‐affective biases in healthy individuals
por: Armand, Sophia, et al.
Publicado: (2022)

Trait aggression is associated with five‐factor personality traits in males
por: Dam, Vibeke H., et al.
Publicado: (2021)

Predicting Treatment Outcome in Major Depressive Disorder Using Serotonin 4 Receptor PET Brain Imaging, Functional MRI, Cognitive-, EEG-Based, and Peripheral Biomarkers: A NeuroPharm Open Label Clinical Trial Protocol
por: Köhler-Forsberg, Kristin, et al.
Publicado: (2020)

Brain serotonin 4 receptor binding is inversely associated with verbal memory recall
por: Stenbæk, Dea S., et al.
Publicado: (2017)

Cognitive impairment and psychopathology in out-of-hospital cardiac arrest survivors in Denmark: The REVIVAL cohort study protocol
por: Wagner, Mette Kirstine, et al.
Publicado: (2020)

Psychometric Properties of the Verbal Affective Memory Test-26 and Evaluation of Affective Biases in Major Depressive Disorder
por: Hjordt, Liv V., et al.
Publicado: (2020)

Genetic contributions to brain serotonin transporter levels in healthy adults
por: Bruzzone, Silvia Elisabetta Portis, et al.
Publicado: (2023)

Stress-Hormone Dynamics and Working Memory in Healthy Women Who Use Oral Contraceptives Versus Non-Users
por: Høgsted, Emma Sofie, et al.
Publicado: (2021)

Sexual health and serotonin 4 receptor brain binding in unmedicated patients with depression—a NeuroPharm study
por: Rasmussen, Annika Læbo, et al.
Publicado: (2023)

Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
por: Fadahunsi, Nicole, et al.
Publicado: (2022)

Common HTR2A variants and 5‐HTTLPR are not associated with human in vivo serotonin 2A receptor levels
por: Spies, Marie, et al.
Publicado: (2020)

Visual stimuli induce serotonin release in occipital cortex: A simultaneous positron emission tomography/magnetic resonance imaging study
por: Hansen, Hanne Demant, et al.
Publicado: (2020)

Editorial: The psychotherapeutic framing of psychedelic drug administration
por: Beckman, Maria, et al.
Publicado: (2023)

No evidence for a role of the serotonin 4 receptor in five-factor personality traits: A positron emission tomography brain study
por: Stenbæk, Dea Siggaard, et al.
Publicado: (2017)

The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
por: Roseman, Leor, et al.
Publicado: (2014)

The Impact of Hormonal Contraceptive Use on Serotonergic Neurotransmission and Antidepressant Treatment Response: Results From the NeuroPharm 1 Study
por: Larsen, Søren Vinther, et al.
Publicado: (2022)

Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension
por: Beaman, Emily Eufaula, et al.
Publicado: (2022)

Short-term oestrogen as a strategy to prevent postpartum depression in high-risk women: protocol for the double-blind, randomised, placebo-controlled MAMA clinical trial
por: Høgh, Stinne, et al.
Publicado: (2021)

Deep phenotyping towards precision psychiatry of first-episode depression — the Brain Drugs-Depression cohort
por: Jensen, Kristian Høj Reveles, et al.
Publicado: (2023)

The Therapeutic Potential of Psilocybin
por: Lowe, Henry, et al.
Publicado: (2021)

Serotonin transporter gene (SLC6A4) variation and sensory processing sensitivity—Comparison with other anxiety‐related temperamental dimensions
por: Licht, Cecilie L., et al.
Publicado: (2020)

Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study
por: Jørgensen, Louise M., et al.
Publicado: (2022)

Homebrewed psilocybin: can new routes for pharmaceutical psilocybin production enable recreational use?
por: Gibbons, William J., et al.
Publicado: (2021)

Psilocybin: the magic medicine for depression?
por: Corrigan, Amber Elyse, et al.
Publicado: (2021)

Psilocybin: From Serendipity to Credibility?
por: Rucker, James J., et al.
Publicado: (2021)

Electrical spiking of psilocybin fungi
por: Gandia, Antoni, et al.
Publicado: (2022)

Psilocybin in Palliative Care: An Update
por: Whinkin, Emily, et al.
Publicado: (2023)

Psilocybin desynchronizes brain networks
por: Siegel, Joshua S, et al.
Publicado: (2023)

Association between brain serotonin 4 receptor binding and reactivity to emotional faces in depressed and healthy individuals
por: Sankar, Anjali, et al.
Publicado: (2023)

Psychometric Properties and Validation of the EMOTICOM Test Battery in a Healthy Danish Population
por: Dam, Vibeke H., et al.
Publicado: (2019)

Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review
por: Heuschkel, Kristin, et al.
Publicado: (2020)

Metabolic engineering of Saccharomyces cerevisiae for the de novo production of psilocybin and related tryptamine derivatives
por: Milne, N., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_590vpvbe4nvc2pq70nbpbfis4n